OpenAlex
PricingAboutJobs
Log inGet started
Work

Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

HTML

Year: 2012
Type: conference-abstract
Source: Cancer Research
DOI: 10.1158/0008-5472.sabcs12-s5-5
Authors: E Romond, VJ Suman, J-H Jeong, GW Sledge, CE Geyer, S Martino, P Rastogi, J Gralow, SM Swain, E Winer, G Colon-Otero, C Hudis, S Paik, N Davidson, EP Mamounas, JA Zujewski, N Wolmark, EA Perez
Institutions: MedStar Washington Hospital Center, National Institutes of Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, University of Kentucky, University of Pittsburgh, University of Washington, Aultman Hospital, Allegheny General Hospital, Angeles Clinic and Research Institute, Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, The University of Texas Southwestern Medical Center
Language: English

Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: trastuzumab, HER2-positive breast cancer, adjuvant chemotherapy, overall survival, doxorubicin-cyclophosphamide, paclitaxel, disease-free survival, combined analysis
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W1997127252
Cites:
Cited by: 49
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security